Gusacitinib

Gusacitinib (ASN002) is an investigational drug which acts as a pan-Janus kinase inhibitor, binding with similar affinity at JAK1, JAK2, JAK3 and TYK2, and also inhibiting spleen tyrosine kinase (SYK). It is taken orally and was developed for the treatment of eczema and dermatitis.